Oncology Pulse Masthead

May 2023

Changes ahead in the mix of new oncology agents

  • 80 new oncology drugs have been approved since 2018, with targeted therapy accounting for the bulk of these new drugs
  • 2022 saw fewer approvals than in recent years, but a more diverse set of approaches and MOAs were approved in 2022 and are "on deck" (positive pivotal data) in 2023
  • Implications of the Inflation Reduction Act (IRA) and recent FDA guidance around accelerated approval portend changes to the "fast-to-market" imperative
View as PDF

2023 could see approval of several new MOAs, as well as cell therapy for solid tumors and multiple bispecific T cell engagers

Key Questions for 2023

We'll Be at ASCO!

pzhang@bluestarbio.com

eolsen@bluestarbio.com

mwhang@bluestarbio.com

efarah@bluestarbio.com

A few abstracts we'll be watching...

LinkedIn

« Back to Pulse List

Oncology Pulse is our e-newsletter that looks at recent treads and promising directions in cancer treatments. Add your name to our maillist to receive future issues.